

TITLE

Almond Consumption for 8 Weeks Altered Host and Microbial Metabolism in Comparison to a Control Snack in Young Adults

AUTHORS

Jaapna Dhillon^{1,2}, John W. Newman^{3,4,5}, Oliver Fiehn³, and Rudy M. Ortiz²

1. Department of Nutrition and Exercise Physiology, University of Missouri, Columbia
2. Department of Molecular and Cell Biology, University of California, Merced
3. NIH West Coast Metabolomics Center, University of California, Davis
4. Department of Nutrition, University of California, Davis
5. Obesity and Metabolism Research Unit, USDA □ Agricultural Research Service Western Human Nutrition Research Center, University of California, Davis

Corresponding Author: Jaapna Dhillon, PhD
Department of Nutrition and Exercise Physiology
School of Medicine
University of Missouri, Columbia
204 Gwynn Hall
Columbia, MO 65211
Email: jdhillon@missouri.edu

SUPPORT

The present study was supported by the Almond Board of California (PI: RMO). JD was supported by the National Institute On Minority Health And Health Disparities of the

National Institutes of Health under award numbers K99MD012815 and R00MD012815 at the time of this work. Additional support was provided by USDA Project 2032-51530-025-00D (JWN). The USDA is an equal opportunity provider and employer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. Moreover, mention of commercial products is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the USDA or NIH. The funders had no role in the study conception, design and implementation, data collection, data analysis, or interpretation of results.

ABBREVIATIONS

AUTHOR DISCLOSURES

RMO discloses grants and non-financial support from Almond Board of California for conducting the study. JD, OF, JWN have no conflicts of interest.

1 ABSTRACT

2 Almond consumption can improve cardiometabolic (CM) health. However, the mechanisms
3 underlying those benefits are not well characterized. This study explored the effects of
4 consuming a snack of almonds vs. crackers for 8 weeks on changes in metabolomic profiles
5 in young adults (clinicaltrials.gov ID: NCT03084003). Participants (n=73, age: 18-19 years,
6 BMI: 18-41 kg/m²) were randomly assigned to consume either almonds (2 oz/d, n=38) or an
7 isocaloric control snack of graham crackers (325 kcal/d, n=35) daily for 8 weeks. Blood
8 samples were collected at baseline prior to and at 4 and 8 weeks after the intervention.
9 Metabolite abundances in the serum were quantified by hydrophilic interaction
10 chromatography quadrupole (Q) time-of-flight (TOF) mass spectrometry (MS/MS), gas
11 chromatography (GC) TOF MS, CSH-ESI (electrospray) QTOF MS/MS, and targeted
12 analyses for free PUFAs, total fatty acids, oxylipins and endocannabinoids. Linear mixed
13 model analyses with baseline-adjustment were conducted, and those results were used for
14 enrichment and network analyses. Microbial community pathway predictions from 16S
15 rRNA sequencing of fecal samples was done using PICRUST2. Almond consumption
16 enriched unsaturated triglycerides, unsaturated phosphatidylcholines, saturated and
17 unsaturated lysophosphatidylcholines, tricarboxylic acids, and tocopherol clusters (p<0.05).
18 Targeted analyses reveal lower levels of omega-3 total fatty acids (TFAs) overall in the
19 almond group compared to the cracker group (p<0.05). Microbial amino acid biosynthesis,
20 and amino sugar and nucleotide sugar metabolism pathways were also differentially enriched
21 at the end of the intervention (p<0.05). The study demonstrates the differential effects of
22 almonds on host tocopherol, lipid, and TCA cycle metabolism with potential changes in
23 microbial metabolism, which may interact with host metabolism to facilitate the CM benefits.

24

25 KEYWORDS

26 Lipidomics, metabolism, microbiome, precision nutrition, microbiome

27

28 INTRODUCTION

29 The complex interplay among the host genome, the gut microflora, and environmental
30 (diet, lifestyle, socioeconomic determinants etc.) and behavioral factors modulates multiple
31 metabolic pathways resulting in specific biological and physiological effects (1) that
32 ultimately influence health and disease. Metabolomic approaches that integrate large swaths
33 of metabolism provide an experimental advantage by mapping metabolites in such a fashion
34 that putative mechanisms can be elucidated as demonstrated in the SuGAR Project (2–4).

35 To date, nutritional metabolomics has focused more on the identification of biomarkers
36 for foods and diet-related disease states (5). Over the past decade, potential biomarkers or
37 metabolite signatures have been identified for several foods including red meat (6), coffee
38 (7), citrus fruits (8), cruciferous vegetables (9), almonds (10), and other plant foods (11).
39 However, there is limited research on the elucidation of molecular mechanisms responsible
40 for the effects of dietary interventions (5). The potential of identifying changes in metabolic
41 pathways is improving with advancements in analytical chemistry techniques, metabolite
42 databases, and computational tools.

43 Another important consideration in nutritional metabolomics is the gut microbiome-host
44 interactions (12). A considerable number of metabolomic features that are influenced by
45 dietary changes can also be modifiable by the gut microbiome. For example, the metabolomic
46 signatures observed in human fecal donor samples were reproduced in the urine and feces of
47 humanized mice (13). Changes to the diets fed to humanized mice altered those metabolomic
48 signatures and mirrored changes in bacterial community composition (13).

49 Nut consumption is associated with reduced cardiovascular disease mortality (14).

50 Moreover, interventional studies demonstrate favorable effects of nut consumption on clinical

51 lipid profiles, blood glucose, and endothelial function (14). Nut studies employing
52 metabolomics have identified potential urinary biomarkers and signatures of walnut (15) and
53 pistachio (16) as well as urinary (17) and plasma (18) biomarkers of mixed nut consumption
54 and erythrocyte signatures of almond consumption (10). These metabolites collectively
55 include markers of fatty acid metabolism, ellagitannin-derived microbial metabolites,
56 microbial-derived phenolic metabolites, and intermediate tryptophan/serotonin pathway
57 metabolites. There are limited -omics data that map the changes in metabolic pathways
58 following the chronic consumption of nuts. The high unsaturated fat content and relatively
59 low available carbohydrate content of almonds has the potential to change carbohydrate and
60 lipid metabolism.

61 We have previously demonstrated the effects of almond snacking for 8 weeks on
62 cardiometabolic (19) and microbiome profiles (20) in young adults. The unique nutrient
63 profile of almonds improved postprandial glucoregulation (19) and alpha-diversity of the gut
64 microbiome (20) compared to cracker snacking at the end of the 8-week intervention. Here,
65 we use untargeted and targeted metabolomics to capture the alterations in serum metabolites
66 involved in metabolic pathways with 8 weeks of almond snacking.

67 METHODS

68 All procedures involving human subjects were approved by the University of
69 California (UC) Merced Institutional Review Board. The study is registered on
70 ClinicalTrials.gov (registration number: NCT03084003). The samples used in the present
71 study were collected previously and presented separately here to provide the requisite focus
72 on these results, which complement our previous studies (21,22)

73

74 *Participants*

75 Seventy-three (41 women and 32 men) young adults (18–19 years old, BMI: 18-41
76 kg/m²) were recruited to participate in an 8-week randomized, controlled, parallel-arm
77 intervention examining the effects of almond vs. cracker snacking on cardiometabolic,
78 microbiome, and metabolomics outcomes. The eligibility criteria were as follows: (a) 18-19
79 years of age, (b) newly enrolled, 1st-year college students with no nut allergies, (c) non-
80 smokers, and (d) no diagnosed cardiometabolic disorders. Participants were recruited via
81 advertisements and those who met eligibility criteria provided written, informed consent
82 before beginning the study.

83

84 *Study design and protocol*

85 The primary study design has been described previously (19). The sample size
86 calculations for the primary study were based on glucoregulatory profiles at the end of the
87 8-week intervention (19). Participants were randomized into one of two study arms: (1)
88 almonds and (2) crackers. Participants in the almond group (n=38) consumed 57 g/d (2 oz;
89 327 kcal; 14% carbohydrate (8g fiber), 74% fat, 13% protein) of whole, dry-roasted almonds.
90 Participants in the cracker group (n=35) served as the isocaloric control consuming 5 sheets
91 (77.5 g/d) of graham crackers (325 kcal; 74% carbohydrate (2.5 g fiber, 20% fat, 6% protein).
92 The cracker group was asked to avoid all nuts, seeds, and nut-containing products.
93 Anthropometric, biochemical, dietary and microbiome data were collected and analyzed as
94 described previously (23). Serum samples were collected at baseline prior to starting the
95 intervention and at 4 and 8 weeks as previously described (21) and stored at –80 °C.

96

97 *Gas chromatography (GC) time-of-flight (TOF) mass spectrometry (MS) data acquisition and*
98 *processing*

99 Serum aliquots were thawed, extracted, trimethylsilyl-derivatized, and the metabolite
100 abundances quantified by GC/TOF MS as previously described (24). Derivatized samples
101 were analyzed on an Agilent 7890 A gas chromatograph (Santa Clara, CA) equipped with a
102 30 m x 0.25 mm i.d., 25 μ m Rtx5Sil-MS column with an additional 10 m integrated guard
103 column (Restek, Bellefonte PA) (25,26). Mass spectrometry was performed using a Leco
104 Pegasus IV time-of-flight mass spectrometer (St. Joseph, MI). Thirteen internal standards,
105 C8–C30 fatty acid methyl esters, were added to samples for retention time alignment
106 markers, quality control purposes and quantification corrections.

107 Raw mass spectra were preprocessed using ChromaTOF vs. 4.0 and were further
108 processed using the BinBase algorithm and database for metabolite identification (27,28).
109 Quantification of metabolites are reported as peak heights.

110 All samples were analyzed in one batch, and data quality and instrument performance
111 were constantly monitored using quality controls comprised of pooled serum samples and
112 injected every 10 samples.

113

114 *Hydrophilic Interaction chromatography (HILIC) quadrupole (Q) time-of-flight (TOF)*

115 *MS/MS data acquisition and processing*

116 Serum aliquots were extracted as previously described (29). The bottom layer of the
117 2-phase solution was used for HILIC-MS. Extracts were analyzed on a Agilent 1290 Infinity
118 II LC System (Santa Clara, CA) with a 150 mm long, 2.1 mm interdiameter (id), and 1.7 μ m
119 particles Waters Acquity UPLC BEH Amide column protected by a short guard column.
120 Mass spectrometry was performed using a Sciex 6600 TTOF mass spectrometer
121 (Framingham, MA) with resolution R=10,000 for positively charged polar compounds.
122 Nineteen internal standards, optimized for HILIC-MS, were added to samples for retention
123 time alignment markers, quality control purposes, and quantification corrections.

124 Raw data were processed using MS-DIAL (version 3.2) (30). Quantification of
125 metabolites are reported as peak heights. All samples were analyzed in one batch, and data
126 quality and instrument performance were constantly monitored using blanks and quality
127 controls, which were comprised of pooled plasma samples (BioIVT) and injected every 10
128 samples.

129

130 *Charged Surface Hybrid electrospray (CSH-ESI) QTOF MS/MS data acquisition and*
131 *processing*

132 Serum aliquots were extracted as previously described (29). The top layer of the 2-
133 phase solution was used for lipidomic analyses. Extracts were analyzed on an Agilent 1290
134 Infinity II LC System (Santa Clara, CA) with a 100 mm long, 2.1 mm id, and 1.7 μm
135 particles Waters Acquity UPLC CSH C18 column protected by a short guard column. Mass
136 spectrometry was performed using an Agilent 6530 QTOF mass spectrometer with resolution
137 $R=10,000$ for positively charged lipids and an Agilent 6530b QTOF mass spectrometer with
138 resolution $R=20,000$ for negatively charged lipids. Twenty-four internal standards, optimized
139 for lipidomics, were added to samples for retention time alignment markers, quality control
140 purposes, and quantification corrections.

141 Raw data were processed using MS-DIAL (version 2.8) (30). Quantification of
142 metabolites are reported as peak heights. All samples were analyzed in one batch, and data
143 quality and instrument performance were constantly monitored using quality controls, which
144 were comprised of pooled plasma samples (BioIVT) and injected every 10 samples.

145

146 *Targeted analyses of total fatty acids*

147 Serum aliquots were extracted, derivatized, and analyzed as previously described
148 (31,32). Extracts in 8:1 methanol/toluene were transformed into fatty acid methyl esters

149 (FAMES) by sequential incubation with methanolic sodium hydroxide and methanolic
150 hydrochloric acid, isolated in hexane from neutralized solutions and quantified by GC-MS.
151 Briefly, FAMES were separated on a 30m x 0.25mm, 0.25 μ m DB-225ms on a 6890 gas
152 chromatogram interfaced with a 5973A mass selective detector (Agilent Technologies) and
153 quantified against 6- to 8-point calibration curves. Data was acquired with Chemstation v
154 E.02 and processed with MassHunter v. 3.0.2. Results were corrected for recoveries of
155 perdeuterated palmitate introduced as a triglyceride prior to extraction.

156

157 *Targeted analyses of free PUFAs, oxylipins, and endocannabinoids*

158 Serum aliquots were extracted as previously described (33). Residues in isopropanol
159 extracts were separated on a 2.1 mm x 150 mm, 1.7 μ m BEH C18 column (Waters, Milford,
160 MA) and detected by electrospray ionization with multi reaction monitoring on a API 6500
161 QTRAP (Sciex; Redwood City, CA). Metabolites were quantified against 7- to 9-point
162 calibration curves of authentic standards and internal standard corrections using
163 modifications as previously reported (2).

164

165 *Univariate analyses of metabolomics data*

166 Data were reported as quantitative ion peak heights and known metabolites were
167 normalized using Systematic Error Removal Using Random Forest (SERRF) normalization
168 (34). SERRF consistently produced the lowest cross-validated relative standard deviation
169 (cvRSD) for QC samples compared to 14 other commonly used normalization methods (34).
170 Metabolites with QC RSD > 50% were excluded from further analyses. For HILIC-MS,
171 metabolite intensities in samples were also compared to blanks. Metabolites that showed no
172 significant differences between sample and blank (i.e. Wilcoxon test p-value > 0.05) and
173 those with a median sample to blank ratio < 1 were also excluded from further analyses. Data

174 not meeting normality assumptions were transformed using Johnson's family of
175 transformations. However, only non-transformed data and means are presented for
176 interpretation of biological significance.

177 We took a 2-step approach to the analyses. The first step focused on selecting the
178 identified metabolites that showed a significant overall time effect in a linear, mixed model
179 analysis with week (baseline, week 4, and week 8) as the factor. The time effect p-values for
180 metabolites were corrected for multiple hypotheses testing using Benjamini-Hochberg
181 correction (false discovery rate (FDR) adjusted p-value). Metabolites that demonstrated a
182 significant (FDR < 0.05) time effect were selected for further analyses. The second step
183 comprised of the selected metabolites undergoing a linear, mixed model analysis with week
184 (week 4 and week 8), snack group, and a week-by-snack group interaction as factors where
185 the analyses were adjusted for baseline values. When significant interaction effects were
186 observed, simple effects for time and snack were carried out and pairwise comparisons were
187 adjusted for multiple comparisons using Bonferroni correction. For any correlation analyses
188 by groups, the significance of the difference between correlation coefficients was assessed
189 using Fisher r to z transformation. Future analyses will explore the effects of BMI, sex, and
190 metabolic risk factors which are outside the scope of this manuscript.

191

192 *Chemical enrichment analysis*

193 Chemical similarity enrichment analysis was conducted using ChemRICH, which is a
194 software for metabolomic datasets that uses medical subject headings and Tanimoto
195 substructure chemical similarity coefficients to cluster metabolites into non-overlapping
196 chemical groups (35). The quantitative data set comprised of the baseline-adjusted overall
197 snack effect p-values of all annotated metabolites. Statistically significant p-values for

198 clusters of metabolites were obtained by self-contained Kolmogorov–Smirnov tests and
199 adjusted for FDR.

200

201 *Network analysis*

202 Network analysis was used to explore differences between the almond and cracker
203 groups within a biochemical and structural context. A biochemical and chemical similarity
204 network was created for all measured metabolites with KEGG and PubChem CID identifiers
205 using MetaMapR (36). Metabolites involved in biochemical transformations were connected
206 based on product-precursor relationships defined in the KEGG RPAIR database. Metabolites
207 sharing structural properties defined in PubChem Substructure Fingerprints (37) were
208 connected at a Tanimoto similarity threshold ≥ 0.7 . The quantitative data set comprised of the
209 overall effect size (Hedge's g for almond vs cracker groups) and baseline-adjusted snack
210 effect p -values. In cases of significant time \times group effects, the larger magnitude of effect
211 size between week 4 or week 8 was presented. Since this was an exploratory analysis, the
212 p -values were not FDR adjusted. The network was then visualized in Cytoscape 3.7.2 (38)
213 using the yFiles organic layout and visual separation of clusters in the network was facilitated
214 with the GLay community clustering algorithm (39). Significant metabolites which did not
215 have KEGG identifiers are included as independent nodes with manually annotated edges in
216 their respective pathway clusters.

217

218 *Microbial community metabolic potential*

219 The functional potential of the microbial community was predicted from 16S rRNA
220 using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States
221 (PICRUST2) (40,41), which uses hidden-state prediction algorithms to infer gene families (i.e.
222 KEGG orthologs (KO) here) and MinPath for inference of pathway abundances. The gene

223 abundances were analyzed by constructing a combined time x group factor and fitting the
224 within-subject correlation in a linear model blocked on subject in the limma-voom pipeline in
225 R (42,43). Pre-planned contrasts were constructed from the model. KO enrichment of
226 differentially expressed ($p < 0.05$ corrected for multiple contrast testing) metabolic pathway
227 genes for each contrast were conducted in MicrobiomeAnalyst (44) via hypergeometric tests
228 to evaluate if specific metabolic pathways are represented more often than expected by
229 chance. P-values for pathway enrichment were adjusted for FDR.

230 We identified the serum metabolites potentially derived from gut microbial
231 metabolism using the Annotation of Metabolite Origins via Networks (AMON) tool (45).
232 Participants gut microbiomes were profiled previously via 16S rRNA sequencing of stool
233 samples (46). The input dataset submitted to AMON comprised of microbiome KO
234 identifiers, KO list of the human genome, and KEGG compound IDs of the metabolomics
235 data. The metabolites produced or metabolized by gut microbiome are annotated in the
236 networks (**Figure 1**). The contribution of the microbial community metabolism to the serum
237 metabolite abundances was evaluated using MIMOSA2 (47,48).

238

239 RESULTS

240 *Participant characteristics and findings from parent study*

241 Participant demographic, clinical and dietary characteristics (19) and gut microbiome
242 profiles (46) have been described in detail previously.

243 *SERRF normalization reduced the cvRSD of QCs in the untargeted analyses*

244 For GC-TOF MS, the cvRSD of QCs decreased from 23.7% (raw) to 12.7%
245 (SERRF). For ESI (-) QTOF-MS, cvRSD of QCs decreased from 14% (raw) to 6.5%
246 (SERRF). For ESI (+) QTOF-MS, cvRSD of QCs decreased from 17.9% (raw) to 4.5%
247 (SERRF). For HILIC-MS, cvRSD of QCs decreased from 15% (raw) to 10% (SERRF).

248

249 *Data quality of the targeted total fatty acid, oxylipin, endocannabinoid, and non-esterified*

250 *PUFA analyses*

251 Surrogate recoveries were between 28 - 108% for all oxylipin and endocannabinoid
252 analytes and 54% for fatty acids. Analytical precision was assessed by duplicate analysis of a
253 plasma pool control (UTAK) (n=20) and was excellent with 83% of oxylipin and
254 endocannabinoid analytes with <30% RSD and 63% of fatty acids with <30% RSD for the
255 UTAKs analyzed, respectively.

256

257 *Metabolomic coverage*

258 A total of 542 metabolites were quantified by GC-MS of which 150 had known
259 PubChem identifiers, 2747 were quantified by QTOF-MS of which 470 had known PubChem
260 identifiers, and 2427 were quantified by HILIC-MS of which 232 had known PubChem
261 identifiers. The targeted analyses detected and quantified 23 total fatty acids, 29 oxylipins, 10
262 endocannabinoids, and 5 non-esterified PUFAs above the limits of detection. In total, 692
263 metabolites were uniquely identified after removal of duplicates and quality checks.

264

265 *Top metabolites*

266 A total of 129 untargeted metabolites had significant (FDR<0.05) overall time effect.
267 The means of those untargeted metabolites that had baseline-adjusted snack and snack x time
268 p-values <0.05 are shown in **Table 1**. Almond consumption resulted in overall greater levels
269 of alpha-tocopherol, ecgonine, erucic acid, indole-3-carboxaldehyde,
270 lysophosphatidylcholines (18:0), and oleamide, and lower levels of 3-
271 hydroxyisovaleroylcarnitine and CE (16:0) than cracker consumption (baseline-adjusted
272 snack effect, p<0.05).

273 Several metabolites depicted significant snack and time interactions (baseline-
274 adjusted snack x time effect, $p < 0.05$, **Table 1**). Contrasts depict that cracker consumption
275 resulted in greater levels of isomaltose at week 4 compared to week 8 ($p < 0.05$). Almond
276 consumption resulted in greater levels of oxoproline, methyl O-D-galactopyranoside, and
277 N2,N2-Dimethylguanosine at week 4 compared to week 8 ($p < 0.05$).

278 The means of specific targeted metabolites that showed significant ($p < 0.05$) baseline-
279 adjusted snack and snack x time effects are shown in **Table 2**. Almond consumption resulted
280 in overall lower levels of NEFA and TFA fractions of alpha-linolenic acid (ALA) and
281 eicosapentaenoic acid (EPA), and eicosatetraenoic acid (ETA) n3 NEFA, and ALA
282 metabolites, 9-HOTE, 15(16)-EpODE, and docosahexaenoic acid (DHEA) compared to
283 cracker consumption (baseline-adjusted snack effect, $p < 0.05$). The omega-6:omega-3 and
284 DPA:EPA fatty acid ratios were higher, and Σ omega-3 and palmitoleic acid:palmitic acid
285 ratio were lower in response to almond consumption compared to cracker consumption
286 (baseline-adjusted snack effect, $p < 0.05$).

287

288 *Chemical similarity enrichment analysis of metabolites indicates greater changes in*
289 *unsaturated triglycerides and lysophosphatidylcholine metabolism with almond consumption*

290 ChemRICH analysis, which was conducted on baseline-adjusted metabolite values,
291 mapped 625 of the identified (untargeted) metabolites to 58 non-overlapping chemical
292 classes. Seven clusters were significantly different between the almond and cracker groups
293 (FDR-adjusted p-value < 0.05) overall. Almond consumption enriched unsaturated
294 triglycerides, unsaturated phosphatidylcholines, saturated and unsaturated
295 lysophosphatidylcholines, sphingomyelins, and tricarboxylic acids clusters. The key
296 metabolites in each of those clusters are depicted in **Table 3**. The tocopherol cluster was also
297 influenced with almond consumption overall (FDR-adjusted p-value < 0.05) with gamma-

298 tocopherol significantly decreased ($p<0.05$) and alpha-tocopherol increased compared with
299 cracker consumption (**Table 3**).

300 *Network analysis of metabolites depicts an alteration in compounds involved in lipid and*
301 *tocopherol metabolism in response to almond consumption*

302 Metabolites were clustered into groups based on biochemical and structural
303 similarities. Network clusters were largely comprised of primary and intermediate
304 metabolites involved in amino acid, carbohydrate, lipid, and nucleotide metabolism (**Figure**
305 **1**). More specifically, clusters of amines/amides, TCA cycle metabolites, and carnitine and
306 tocopherol metabolism were also identified (**Figure 1**).

307

308 *Carbohydrate metabolism*

309 The almond group had greater levels of metabolites involved in the TCA cycle such
310 as succinic, aconitic, and isocitric acids, and lower levels of hexitol compared to cracker
311 consumption (Hedge's g : 0.34-0.59, snack effect $p<0.05$). Almond consumption resulted in
312 greater levels of citric acid at week 4 ($g=0.84$) and lower levels of raffinose ($g=0.26$),
313 isomaltose ($g=0.32$), gluconic acid ($g=0.48$), methyl O-D-galactopyranoside ($g=0.41$), and
314 2-alpha-mannobiose ($g=0.28$) at week 8 and lower levels of ribonic acid at week 4 ($g=0.24$)
315 compared to cracker consumption (time x snack effect, $p<0.05$).

316

317 *Amino acid metabolism*

318 Almond consumption largely elicited lower levels of metabolites involved in amino
319 acid metabolism such as cyclo (Leu-Pro), alpha-methyl-histidine, and pipercolinic acid
320 ($g=0.31-0.65$) and higher levels of phenylacetylglutamine ($g=0.27$) and indole-3-
321 carboxaldehyde ($g=0.56$) compared to cracker consumption (snack effect, $p<0.05$).
322 Differential time x snack effects ($p<0.05$) were noted as well with 4-acetamidobutyric acid,

323 alpha-keto-gamma-(methylthio) butyric acid, and oxoproline lower with almond consumption
324 at week 8 ($g=0.27-0.39$) but not at week 4. N-acetylglycine was greater in the almond group
325 at week 4 ($g=0.61$) and N.epsilon.-methyl-L-lysine was lower in the almond group at week 8
326 ($g=0.41$).

327

328 *Lipid metabolism*

329 The alterations in lipid metabolites such as LPC, PC, TG, and SM, and fatty acids and
330 their derivatives with almond consumption have been described in the previous sections.

331 Other significant metabolites include 3-hydroxyisovalerylcarnitine ($g=0.36$) and
332 palmitoylcarnitine ($g=0.31$), which was increased in the almond group (snack effect, $p<0.05$).

333 Differential time x snack effects ($p<0.05$) were noted for acetylcarnitine ($g=0.47$) and
334 glycerophosphocholine ($g=0.12$), both being greater with almond consumption at week 4.

335 LPC (20:0) and LPC (20:1) were greater in the almond group at week 8 ($g=0.72-0.76$, time x
336 snack effect $p<0.05$).

337

338 *Metabolism of cofactors and vitamins*

339 Almond consumption elicited greater levels of alpha-tocopherol ($g=0.49$) and lower
340 levels of gamma-tocopherol ($g=0.53$) and trigonelline ($g=0.56$) overall compared to cracker
341 consumption (snack effect $p<0.05$).

342

343 *Nucleoside and nucleotide metabolism*

344 Almond consumption elicited lower levels of 7-methylguanosine overall ($g=0.37$,
345 snack effect $p<0.05$). Differential time x snack effects ($p<0.05$) were noted for
346 1-methyladenosine A and N2,N2-dimethylguanosine with greater levels at week 4 ($g=0.29-$
347 0.45) and lower levels at week 8 for the almond group ($g = 0.32$).

348

349 *Potential microbiome community-dependent metabolism*

350 There were no significantly enriched pathways detected for the differentially
351 expressed (almond vs. cracker) genes at baseline (FDR>0.05, **Supplemental Table 1**).
352 Overrepresentation analysis of the differentially expressed metabolic pathway genes at week
353 8 found significant enrichment (FDR<0.05, **Supplemental Table 1**) of biosynthesis of amino
354 acids, amino sugar and nucleotide sugar metabolism, starch and sucrose metabolism, and
355 fructose and mannose metabolism.

356 AMON identified 94 metabolites in the serum as being potentially produced or
357 metabolized by microbes isolated from 16S sequencing of host stool samples, which are
358 annotated in **Figure 1**. MIMOSA predicted the microbial community potential (CMP) of 81
359 metabolites out of which 67 overlapped with AMON results. The almond group at week 8
360 demonstrated a positive correlation of serum N-acetyl-D-mannosamine (R-square: 0.14,
361 p<0.05) (**Supplemental Figure 1**), and a negative correlation of serum L-cysteine (R-square:
362 0.16, p<0.05) with the CMP scores, which were significantly different from the cracker group
363 (p<0.05 for difference in correlation coefficients between groups). The cracker group at week
364 8 only demonstrated a negative correlation of 5(S)-HETE (R-square: 0.15, p<0.05) with the
365 CMP scores. The negative association between a metabolite's levels and its CMP could
366 potentially be due to missing reactions in the KEGG database or effects other than
367 metabolism (48).

368

369 **DISCUSSION**

370 The metabolomics analyses in our study demonstrated shifts in host metabolism with
371 almond consumption particularly that of tocopherol, lipids, and the TCA cycle with some

372 differential time effects noted as well. The study also suggests that changes in microbial
373 metabolism could potentially influence host metabolism.

374 Almond consumption for 8 weeks increased alpha-tocopherol and decreased gamma-
375 tocopherol, which is supported by targeted studies (49). This could be due to the preferential
376 uptake of alpha-tocopherol in the liver when dietary intake is increased and reduced retention
377 of other tocopherol forms (50). Increased alpha-tocopherol is typically considered a
378 biomarker for compliance with almond consumption. The increase in alpha-tocopherol was
379 most prominent at week 4 and appeared to have plateaued at week 8 suggesting that levels
380 may reach a saturable limit by week 4. Previous studies have demonstrated that in
381 participants with normal plasma alpha-tocopherol concentrations of 25 μM , the plasma
382 concentrations do not increase more than 2-3 fold even upon supplementation (50–52) further
383 suggesting that levels of alpha-tocopherol are saturable. In a dose-dependent almond study,
384 10% of energy intake from almonds resulted in a 13.7 % increase, and 20% in 18.7 %
385 increase in plasma alpha-tocopherol over 4 weeks (49). In our study, the decrease in the
386 magnitude of alpha-tocopherol concentration change (over 8 weeks) as baseline
387 concentrations increase also suggests the presence of a saturable pool (**Supplemental Figure**
388 **2**). Our dietary recall data also indicates an increase in alpha-tocopherol over 4 weeks with no
389 further change beyond week 4 with almond consumption (21). Given the differential response
390 in alpha- and gamma-tocopherol to almond consumption, we propose that the ratio may serve
391 as a robust marker of dietary compliance when the intervention may be of a lesser quantity
392 and/or duration to not reach saturable levels in circulation.

393 Almond consumption was also associated with greater levels of phosphatidylcholines,
394 and its derivative LPC species, which have been reported to influence diverse cell types such
395 as endothelial cells, adipocytes, hepatocytes, and immune cells (53). Due to the complexity of
396 its metabolism, the role of LPCs in disease causality is controversial (53). In a recent review

397 (53), while *in vitro* studies implicated LPCs in apoptosis and pro-inflammatory conditions,
398 clinical studies demonstrated that circulating LPCs were inversely associated with
399 cardiovascular diseases. Other studies showed lower levels of diverse LPC species with
400 obesity (54) and negative associations with inflammatory markers and insulin resistance
401 (54,55) suggesting that LPCs may protect against metabolic disorders. Analyses conducted
402 on a subset of participants in the current study demonstrated significant ($p < 0.05$) negative
403 correlations of LPCs with inflammatory markers. Moreover, almond consumption for 8
404 weeks elicited positive correlations ($r = 0.30-0.55$) of IL-6 with various LPC species including
405 LPC (20:1), LPC (18:0), and LPC (18:1), and IL-10 with LPC (22:4) whereas negative
406 correlations ($r = 0.2-0.41$) were identified in the cracker group ($p < 0.05$ for group
407 comparisons). IL-10 is an anti-inflammatory cytokine while IL-6 can be either inflammatory
408 or anti-inflammatory (56). These relationships suggest that LPCs and inflammatory markers
409 in relatively healthy adults are mediated by dietary conditions and that chronic almond
410 consumption may have a role to play in immune health through the maintenance or increase
411 in LPCs. However, other considerations for interpretation of LPC effects across diet studies
412 should include examination of tissues and/or cell types, and comparisons between healthy
413 and diseased states and/or saturated and unsaturated species.

414 Almond consumption generally increased unsaturated triglycerides over 8 weeks.
415 More specifically, the almond group had higher levels of oleamide, which is a fatty acid
416 amide of oleic acid. Surprisingly, the targeted analyses did not detect a difference in oleic
417 acid TFA between groups even though it is the most predominant fatty acid in almonds.
418 However, this inconsistency has been documented previously. For example, in a dose-
419 dependent study, half-dose almonds (37 ± 2 g/d) increased oleic acid in NEFA and TAG
420 fractions; however, the full dose (75 ± 3 g/d) did not demonstrate an increase in NEFA
421 fraction (57). Our dietary data indicates greater oleic acid intake in the almond group

422 compared to the cracker group. The bioaccessibility of lipids from whole almonds during
423 mastication and digestion may limit the amount of fat absorbed through the gastrointestinal
424 tract (58), hence contributing to the incongruency between dietary intake and serum NEFA
425 levels. However, since serum NEFA levels are predominately regulated by adipose
426 triglyceride hydrolysis (59), these results suggest that almond consumption did not alter
427 adipose composition or the rates of adipose lipolysis. Alternatively, because increased oleic
428 acid can stimulate complete fatty acid oxidation (60), the increased intake with almond
429 consumption may have increased oxidation including the oxidation of oleic acid itself to
430 mask the potential to detect an increase in circulating levels. The greater levels of
431 acetylcarnitine particularly at week 4 in the almond group suggests that beta-oxidation of
432 fatty acids was increased and substantiates the data in the literature that increased oleic acid
433 promotes beta oxidations of FFA. Nonetheless, our results suggest that in a free-living study,
434 serum oleic acid may not be a viable biomarker of compliance with almond consumption.

435 Almond consumption also lowered the palmitoleic acid: palmitic acid ratio. A greater
436 ratio is considered a diagnostic marker for early onset non-alcoholic steatohepatitis (61) and
437 associated with the presence of impaired glucose tolerance and T2D (62) suggesting that the
438 lower ratio with almond consumption may be indicative of a protective effect against
439 metabolic disorders.

440 The targeted analysis reveals lower levels of omega-3 total fatty acids (TFAs) in the
441 almond group. More specifically, almond consumption had lower levels of ALA, EPA
442 (measured in NEFA and TFA fractions), ALA oxylipins (9-HOTE and 15(16)-EpODE), and
443 DHEA, the acylethanolamide of the omega-3 derivative of DHA. Interestingly, our 24-hour
444 dietary recall data revealed greater intake of EPA in the almond group compared to the
445 cracker group and no differences in ALA intake by group suggesting that the estimated
446 dietary intake of these fatty acids are not indicative of the actual changes in circulating levels.

447 These discrepancies could be due to the low reproducibility of food omega-3 fatty acids by
448 ASA24 (63). Furthermore, the complex metabolism of omega-3 fatty acids involves a series
449 of enzymatic desaturation and elongation processes, interconversions between FAs, and
450 translocation between different cellular compartments (64) that cannot be captured by
451 estimating dietary intake.

452 The increases in aconitic, citric, isocitric, and succinic acids suggests that almond
453 consumption stimulated the TCA cycle. The TCA cycle is a central metabolic pathway where
454 key byproducts of nutrient digestion such as glucose, fatty acids, and some amino acids
455 converge for energy production (65). The increased activity in the TCA cycle could be due to
456 the higher dietary intake of MUFAs and PUFAs in the almond group. Higher fat intake has
457 been found to elevate TCA cycle intermediates in rats (66) suggesting that increased
458 availability of unsaturated FAs may increase the substrates for TCA cycle activity and in
459 essence, feed the system. While in a recent human study, baseline levels of specific TCA
460 cycle metabolites including isocitrate were associated with greater relative risk of T2D, the
461 Mediterranean diet, a diet high in unsaturated fats, appeared to alleviate this risk (67). As
462 mentioned previously, almond consumption increased acetylcarnitine, which is significant
463 here because it is involved in the movement of acetyl-CoA into the mitochondria during beta-
464 oxidation, thereby providing the raw materials for TCA cycle (68). Thus, the increase in TCA
465 cycle activity may be facilitated by increased acetylcarnitine. These data provide a
466 mechanism by which increased dietary MUFA (oleic acid) (and potentially PUFAs) can
467 improve glucose metabolism (via enhanced TCA cycle activity). In the same subjects studied
468 here, almond consumption improved glucose tolerance (21).

469 Another carnitine derivative, 3-hydroxyisovaleroylcarnitine, which is a degradation
470 byproduct of ketogenic amino acids, was lower in the almond group. This may suggest that
471 biotin intake was increased. Increased circulating levels of 3-hydroxyisovaleroylcarnitine is

472 associated with impaired leucine catabolism due to reduced activity of 3-methylcrotonyl-CoA
473 carboxylase, which is a biotin-dependent enzyme in asymptomatic, marginally biotin
474 deficient adults (69,70). Although ASA24 data does not report biotin values, nuts are
475 considered good sources of biotin and the dietary results suggest that the consumption of
476 biotin-rich foods (red meat and eggs) was increased in the almond group.

477 We have previously documented increased alpha-diversity of the gut microbiome with
478 almond consumption (22). The present analysis shows an enrichment of amino acid
479 biosynthesis and carbohydrate metabolism such as amino sugar and nucleotide sugar
480 metabolism in the almond group at week 8. Our analyses revealed differential snack effects
481 on the microbial community potential of several MIMOSA2-predicted amino acids such as
482 glutamate, glutamine, tryptophan, phenylalanine, and proline (**Supplemental Table 2**).
483 However, the predicted microbial metabolism data are most useful when associated with the
484 metabolomics data. The only compound that was positively predicted at the end of the
485 intervention was N-acetyl-D-mannosamine (ManNAc), which is an acylaminosugar. The
486 microbial community in the almond group at week 8 explained 14% of the variation in serum
487 ManNAc. The analyses further suggest that sialic acid metabolism, which includes
488 biosynthesis of N-acetylneuraminic acid (Neu5Ac) from ManNAc, and catabolism of
489 Neu5Ac to ManNAc and subsequently to ManNAc-6-P, which ultimately enters glycolysis,
490 are involved (71). Although serum ManNAc itself was not significantly different between
491 the almond and cracker groups, we speculate that metabolomics and meta-transcriptomics of
492 stool samples might reveal other interesting relationships associated with almond
493 consumption.

494 Other potential products of microbial metabolism that were differentially influenced
495 by diet included cyclo (Leu-Pro), indole-3-carboxaldehyde, phenylacetylglutamine, and
496 pipercolic acid. Phenylacetylglutamine, which is a conjugate of glutamine and phenylacetate,

497 the latter being derived from microbial metabolism of phenylalanine (72,73), was greater in
498 the almond group. Studies have documented the positive association of
499 phenylacetylglutamine with alpha-diversity (72), which is supported by our study as well
500 (data not shown). Pipecolic acid, which was lower in the almond group, could arise from food
501 intake or produced by gut bacteria on lysine degradation (74). Although, cyclo (Leu-Pro) is a
502 bacterium-derived dipeptide whose functional role isn't well known, literature suggests that
503 cyclodipeptides and their derivatives such as diketopiperazines, contribute to bacterial
504 signaling systems (75–77). Almond consumption also resulted in greater indole-3-
505 carboxaldehyde, which is a tryptophan metabolite that acts as a ligand for the aryl
506 hydrocarbon receptor (AhR) in the intestinal immune cells that stimulate IL-22 production
507 when activated. This activation is important for maintaining gut immunity (78), providing
508 another potential benefit of almond consumption on gut health in addition to promoting
509 alpha-diversity.

510 We used comprehensive analyses to study the serum metabolome of almond versus
511 cracker consumers. The changes in microbial metabolism provide complementary insight into
512 the metabolomics data. However, since we used prediction models for assessing microbial
513 metabolism and community potential, the results should be interpreted with caution and in the
514 context of the exploratory nature of the analyses. Moreover, more than half of the metabolites
515 in our dataset could not be annotated owing to the nature of untargeted metabolomics, and
516 biochemical relationships for most lipid mediators could not be defined due to the inherent
517 limitations of KEGG database for lipidomic datasets. Nonetheless, these data provide
518 significant insights on the effects of chronic almond consumption on metabolic pathways not
519 previously explored. Future analyses will explore effects of factors such as BMI, sex, and
520 metabolic risk on these outcomes.

521 Our results provide a deeper understanding of host TCA cycle and lipid metabolism
522 with almond consumption in relatively healthy young adults. In addition, the findings also
523 shed light into the interconnections between circulating metabolites and microbial
524 metabolism in the context of an almond intervention. More generally, these findings provide
525 further evidence for the potential impacts of dietary changes on host substrate metabolism
526 and associated changes in gut microbe metabolism. Whether the changes in the gut microbe
527 or metabolites influence host metabolism or vice versa remains to be elucidated but these data
528 provide evidence for an association between gut microbe metabolism and host cellular
529 metabolism.

530

531 AUTHOR RESPONSIBILITIES

532 JD and RMO designed and conducted the study. JWN and OF directed the metabolomics
533 analyses and assisted with the data interpretation. JD drafted the manuscript. All authors
534 revised the manuscript and approved the submitted version.

REFERENCES

- 535 1. Rezzi S, Ramadan Z, Fay LB, Kochhar S. Nutritional Metabonomics: Applications
536 and Perspectives. *J Proteome Res American Chemical Society*; 2007;6:513–25.
- 537 2. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 Diabetes
538 Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and
539 Endocannabinoids. *PLOS ONE* 2012;7:e48852.
- 540 3. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH,
541 Newman JW, Garvey WT. Plasma acylcarnitine profiles suggest incomplete long-chain
542 fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic
543 African-American women. *J Nutr* 2009;139:1073–81.
- 544 4. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma
545 metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2
546 diabetic obese African-American women. *PloS One* 2010;5:e15234.
- 547 5. Gibbons H, O’Gorman A, Brennan L. Metabolomics as a tool in nutritional research.
548 *Curr Opin Lipidol* 2015;26:30–4.
- 549 6. Cross AJ, Major JM, Sinha R. Urinary biomarkers of meat consumption. *Cancer*
550 *Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*
551 2011;20:1107–11.
- 552 7. Rothwell JA, Fillâtre Y, Martin J-F, Lyan B, Pujos-Guillot E, Fezeu L, Hercberg S,
553 Comte B, Galan P, Touvier M, et al. New Biomarkers of Coffee Consumption Identified
554 by the Non-Targeted Metabolomic Profiling of Cohort Study Subjects. *PLOS ONE*
555 *Public Library of Science*; 2014;9:e93474.

- 556 8. Heinzmann SS, Brown IJ, Chan Q, Bictash M, Dumas M-E, Kochhar S, Stamler J,
557 Holmes E, Elliott P, Nicholson JK. Metabolic profiling strategy for discovery of
558 nutritional biomarkers: proline betaine as a marker of citrus consumption. *Am J Clin*
559 *Nutr* 2010;92:436–43.
- 560 9. Edmands WMB, Beckonert OP, Stella C, Campbell A, Lake BG, Lindon JC, Holmes E,
561 Gooderham NJ. Identification of human urinary biomarkers of cruciferous vegetable
562 consumption by metabonomic profiling. *J Proteome Res* 2011;10:4513–21.
- 563 10. Dhillon J, Ferreira CR, Sobreira TJP, Mattes RD. Multiple Reaction Monitoring
564 Profiling to Assess Compliance with an Almond Consumption Intervention. *Curr Dev*
565 *Nutr* 2017;1:e001545.
- 566 11. Andersen M-BS, Kristensen M, Manach C, Pujos-Guillot E, Poulsen SK, Larsen TM,
567 Astrup A, Dragsted L. Discovery and validation of urinary exposure markers for
568 different plant foods by untargeted metabolomics. *Anal Bioanal Chem* 2014;406:1829–
569 44.
- 570 12. Goodacre R. Metabolomics of a Superorganism. *J Nutr Oxford Academic*;
571 2007;137:259S-266S.
- 572 13. Marcobal A, Kashyap PC, Nelson TA, Aronov PA, Donia MS, Spormann A, Fischbach
573 MA, Sonnenburg JL. A metabolomic view of how the human gut microbiota impacts
574 the host metabolome using humanized and gnotobiotic mice. *ISME J Nature Publishing*
575 *Group*; 2013;7:1933–43.
- 576 14. Kim Y, Keogh J, Clifton PM. Nuts and Cardio-Metabolic Disease: A Review of Meta-
577 Analyses. *Nutrients* [Internet] 2018 [cited 2020 Jun 22];10. Available from:
578 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316378/>

- 579 15. Garcia-Aloy M, Llorach R, Urpi-Sarda M, Tulipani S, Estruch R, Martínez-González
580 MA, Corella D, Fitó M, Ros E, Salas-Salvadó J, et al. Novel Multimetabolite Prediction
581 of Walnut Consumption by a Urinary Biomarker Model in a Free-Living Population: the
582 PREDIMED Study. *J Proteome Res American Chemical Society*; 2014;13:3476–83.
- 583 16. Hernández-Alonso P, Cañueto D, Giardina S, Salas-Salvadó J, Cañellas N, Correig X,
584 Bulló M. Effect of pistachio consumption on the modulation of urinary gut microbiota-
585 related metabolites in prediabetic subjects. *J Nutr Biochem* 2017;45:48–53.
- 586 17. Tulipani S, Llorach R, Jáuregui O, López-Uriarte P, Garcia-Aloy M, Bullo M, Salas-
587 Salvadó J, Andrés-Lacueva C. Metabolomics unveils urinary changes in subjects with
588 metabolic syndrome following 12-week nut consumption. *J Proteome Res*
589 2011;10:5047–58.
- 590 18. Mora-Cubillos X, Tulipani S, Garcia-Aloy M, Bulló M, Tinahones FJ, Andres-Lacueva
591 C. Plasma metabolomic biomarkers of mixed nuts exposure inversely correlate with
592 severity of metabolic syndrome. *Mol Nutr Food Res* 2015;59:2480–90.
- 593 19. Dhillon J, Thorwald M, De La Cruz N, Vu E, Asghar SA, Kuse Q, Diaz Rios LK, Ortiz
594 RM. Glucoregulatory and Cardiometabolic Profiles of Almond vs. Cracker Snacking for
595 8 Weeks in Young Adults: A Randomized Controlled Trial. *Nutrients* 2018;10:960.
- 596 20. Dhillon J, Li Z, Ortiz RM. Almond Snacking for 8 Weeks Increases Alpha-Diversity of
597 the Gastrointestinal Microbiome and Decreases *Bacteroides fragilis* Abundance
598 Compared to an Isocaloric Snack in College Freshmen. *Curr Dev Nutr [Internet]* [cited
599 2019 Jul 8]; Available from: [https://academic.oup.com/cdn/advance-](https://academic.oup.com/cdn/advance-article/doi/10.1093/cdn/nzz079/5527932)
600 [article/doi/10.1093/cdn/nzz079/5527932](https://academic.oup.com/cdn/advance-article/doi/10.1093/cdn/nzz079/5527932)

- 601 21. Dhillon J, Thorwald M, De La Cruz N, Vu E, Asghar SA, Kuse Q, Diaz Rios LK, Ortiz
602 RM. Glucoregulatory and Cardiometabolic Profiles of Almond vs. Cracker Snacking for
603 8 Weeks in Young Adults: A Randomized Controlled Trial. *Nutrients* 2018;10:960.
- 604 22. Dhillon J, Li Z, Ortiz RM. Almond Snacking for 8 wk Increases Alpha-Diversity of the
605 Gastrointestinal Microbiome and Decreases *Bacteroides fragilis* Abundance Compared
606 with an Isocaloric Snack in College Freshmen. *Curr Dev Nutr* [Internet] Oxford
607 Academic; 2019 [cited 2020 Nov 16];3. Available from:
608 <https://academic.oup.com/cdn/article/3/8/nzz079/5527932>
- 609 23. Dhillon J, Li Z, Ortiz RM. Almond Snacking for 8 wk Increases Alpha-Diversity of the
610 Gastrointestinal Microbiome and Decreases *Bacteroides fragilis* Abundance Compared
611 with an Isocaloric Snack in College Freshmen. *Curr Dev Nutr* [Internet] 2019 [cited
612 2019 Sep 17];3. Available from:
613 <https://academic.oup.com/cdn/article/3/8/nzz079/5527932>
- 614 24. Fiehn O, Wohlgemuth G, Scholz M, Kind T, Lee DY, Lu Y, Moon S, Nikolau B.
615 Quality control for plant metabolomics: reporting MSI-compliant studies. *Plant J Cell*
616 *Mol Biol* 2008;53:691–704.
- 617 25. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic
618 approach for identifying kidney cancer. *Anal Biochem* 2007;363:185–95.
- 619 26. Fiehn O. Extending the breadth of metabolite profiling by gas chromatography coupled
620 to mass spectrometry. *Trends Anal Chem TRAC* 2008;27:261–9.
- 621 27. Fiehn O, Wohlgemuth G, Scholz M. Setup and Annotation of Metabolomic Experiments
622 by Integrating Biological and Mass Spectrometric Metadata. In: Ludäscher B, Raschid

- 623 L, editors. Data Integration in the Life Sciences. Berlin, Heidelberg: Springer; 2005. p.
624 224–39.
- 625 28. Scholz M, Fiehn O. SetupX--a public study design database for metabolomic projects.
626 Pac Symp Biocomput 2007;169–80.
- 627 29. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction
628 by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res 2008;49:1137–
629 46.
- 630 30. Tsugawa H, Cajka T, Kind T, Ma Y, Higgins B, Ikeda K, Kanazawa M, VanderGheynst
631 J, Fiehn O, Arita M. MS-DIAL: data-independent MS/MS deconvolution for
632 comprehensive metabolome analysis. Nat Methods Nature Publishing Group;
633 2015;12:523–6.
- 634 31. Sun Chongxiu, Alkhoury Kenan, Wang Ying I., Foster Greg A., Radecke Christopher
635 E., Tam Kayan, Edwards Christina M., Facciotti Marc T., Armstrong Ehrin J.,
636 Knowlton Anne A., et al. IRF-1 and miRNA126 Modulate VCAM-1 Expression in
637 Response to a High-Fat Meal. Circ Res American Heart Association; 2012;111:1054–
638 64.
- 639 32. Smedes F. Determination of total lipid using non-chlorinated solvents. Analyst The
640 Royal Society of Chemistry; 1999;124:1711–8.
- 641 33. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 Diabetes
642 Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and
643 Endocannabinoids. PLOS ONE 2012;7:e48852.

- 644 34. Fan S, Kind T, Cajka T, Hazen SL, Tang WHW, Kaddurah-Daouk R, Irvin MR, Arnett
645 DK, Barupal DK, Fiehn O. Systematic Error Removal Using Random Forest for
646 Normalizing Large-Scale Untargeted Lipidomics Data. *Anal Chem* 2019;91:3590–6.
- 647 35. Barupal DK, Fiehn O. Chemical Similarity Enrichment Analysis (ChemRICH) as
648 alternative to biochemical pathway mapping for metabolomic datasets. *Sci Rep Nature*
649 *Publishing Group*; 2017;7:1–11.
- 650 36. Barupal DK, Haldiya PK, Wohlgemuth G, Kind T, Kothari SL, Pinkerton KE, Fiehn O.
651 MetaMapp: mapping and visualizing metabolomic data by integrating information from
652 biochemical pathways and chemical and mass spectral similarity. *BMC Bioinformatics*
653 2012;13:99.
- 654 37. Cao Y, Jiang T, Girke T. A maximum common substructure-based algorithm for
655 searching and predicting drug-like compounds. *Bioinformatics* 2008;24:i366–74.
- 656 38. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
657 Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of
658 biomolecular interaction networks. *Genome Res* 2003;13:2498–504.
- 659 39. Su G, Kuchinsky A, Morris JH, States DJ, Meng F. GLay: community structure analysis
660 of biological networks. *Bioinformatics Oxford Academic*; 2010;26:3135–7.
- 661 40. Ye Y, Doak TG. A Parsimony Approach to Biological Pathway
662 Reconstruction/Inference for Genomes and Metagenomes. *PLOS Comput Biol Public*
663 *Library of Science*; 2009;5:e1000465.

- 664 41. Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, Huttenhower
665 C, Langille MGI. PICRUSt2 for prediction of metagenome functions. *Nat Biotechnol*
666 Nature Publishing Group; 2020;38:685–8.
- 667 42. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers
668 differential expression analyses for RNA-sequencing and microarray studies. *Nucleic*
669 *Acids Res* 2015;43:e47–e47.
- 670 43. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model
671 analysis tools for RNA-seq read counts. *Genome Biol* 2014;15:R29.
- 672 44. Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical,
673 functional, and meta-analysis of microbiome data. *Nat Protoc* Nature Publishing Group;
674 2020;15:799–821.
- 675 45. Shaffer M, Thurimella K, Quinn K, Doenges K, Zhang X, Bokatzian S, Reisdorph N,
676 Lozupone CA. AMON: annotation of metabolite origins via networks to integrate
677 microbiome and metabolome data. *BMC Bioinformatics* 2019;20:614.
- 678 46. Dhillon J, Li Z, Ortiz RM. Almond Snacking for 8 Weeks Increases Alpha-Diversity of
679 the Gastrointestinal Microbiome and Decreases *Bacteroides fragilis* Abundance
680 Compared to an Isocaloric Snack in College Freshmen. *Curr Dev Nutr* [Internet] [cited
681 2019 Jul 27]; Available from: [https://academic.oup.com/cdn/advance-](https://academic.oup.com/cdn/advance-article/doi/10.1093/cdn/nzz079/5527932)
682 [article/doi/10.1093/cdn/nzz079/5527932](https://academic.oup.com/cdn/advance-article/doi/10.1093/cdn/nzz079/5527932)
- 683 47. Borenstein Lab. MIMOSA2 [Internet]. 2020. Available from:
684 http://borensteinlab.com/software_MIMOSA2.html

- 685 48. Noecker C, Eng A, Srinivasan S, Theriot CM, Young VB, Jansson JK, Fredricks DN,
686 Borenstein E. Metabolic Model-Based Integration of Microbiome Taxonomic and
687 Metabolomic Profiles Elucidates Mechanistic Links between Ecological and Metabolic
688 Variation. *mSystems* [Internet] American Society for Microbiology Journals; 2016
689 [cited 2021 Mar 22];1. Available from: <https://msystems.asm.org/content/1/1/e00013-15>
- 690 49. Jambazian PR, Haddad E, Rajaram S, Tanzman J, Sabaté J. Almonds in the diet
691 simultaneously improve plasma α -tocopherol concentrations and reduce plasma lipids. *J*
692 *Am Diet Assoc* 2005;105:449–54.
- 693 50. Brigelius-Flohé R, Kelly FJ, Salonen JT, Neuzil J, Zingg J-M, Azzi A. The European
694 perspective on vitamin E: current knowledge and future research. *Am J Clin Nutr*
695 2002;76:703–16.
- 696 51. Dimitrov NV, Meyer C, Gilliland D, Ruppenthal M, Chenoweth W, Malone W. Plasma
697 tocopherol concentrations in response to supplemental vitamin E. *Am J Clin Nutr*
698 1991;53:723–9.
- 699 52. Reaven PD, Witztum JL. Comparison of supplementation of RRR- α -tocopherol and
700 racemic α -tocopherol in humans. Effects on lipid levels and lipoprotein
701 susceptibility to oxidation. *Arterioscler Thromb J Vasc Biol* 1993;13:601–8.
- 702 53. Law S-H, Chan M-L, Marathe GK, Parveen F, Chen C-H, Ke L-Y. An Updated Review
703 of Lysophosphatidylcholine Metabolism in Human Diseases. *Int J Mol Sci* [Internet]
704 2019 [cited 2021 Mar 2];20. Available from:
705 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429061/>
- 706 54. Heimerl S, Fischer M, Baessler A, Liebisch G, Siguener A, Wallner S, Schmitz G.
707 Alterations of Plasma Lysophosphatidylcholine Species in Obesity and Weight Loss.

- 708 PLoS ONE [Internet] 2014 [cited 2021 Feb 25];9. Available from:
709 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207804/>
- 710 55. Wallace M, Morris C, O'Grada CM, Ryan M, Dillon ET, Coleman E, Gibney ER,
711 Gibney MJ, Roche HM, Brennan L. Relationship between the lipidome, inflammatory
712 markers and insulin resistance. *Mol Biosyst* 2014;10:1586–95.
- 713 56. Zhang J-M, An J. Cytokines, Inflammation and Pain. *Int Anesthesiol Clin* 2007;45:27–
714 37.
- 715 57. Nishi S, Kendall CWC, Gascoyne A-M, Bazinet RP, Bashyam B, Lapsley KG, Augustin
716 LSA, Sievenpiper JL, Jenkins DJA. Effect of almond consumption on the serum fatty
717 acid profile: a dose-response study. *Br J Nutr* 2014;112:1137–46.
- 718 58. Grundy MM, Lapsley K, Ellis PR. A review of the impact of processing on nutrient
719 bioaccessibility and digestion of almonds. *Int J Food Sci Technol* 2016;51:1937–46.
- 720 59. Physiological regulation of NEFA availability: lipolysis pathway | Proceedings of the
721 Nutrition Society | Cambridge Core [Internet]. [cited 2021 Apr 28]. Available from:
722 [https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-](https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/physiological-regulation-of-nefa-availability-lipolysis-pathway/81DE2F9FCB84C6A38140D2D7EA63C5B7)
723 [society/article/physiological-regulation-of-nefa-availability-lipolysis-](https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/physiological-regulation-of-nefa-availability-lipolysis-pathway/81DE2F9FCB84C6A38140D2D7EA63C5B7)
724 [pathway/81DE2F9FCB84C6A38140D2D7EA63C5B7](https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/physiological-regulation-of-nefa-availability-lipolysis-pathway/81DE2F9FCB84C6A38140D2D7EA63C5B7)
- 725 60. Lim J-H, Gerhart-Hines Z, Dominy JE, Lee Y, Kim S, Tabata M, Xiang YK, Puigserver
726 P. Oleic Acid Stimulates Complete Oxidation of Fatty Acids through Protein Kinase A-
727 dependent Activation of SIRT1-PGC1 α Complex. *J Biol Chem* 2013;288:7117–26.

- 728 61. Yamada K, Mizukoshi E, Seike T, Horii R, Terashima T, Iida N, Kitahara M,
729 Sunagozaka H, Arai K, Yamashita T, et al. Serum C16:1n7/C16:0 ratio as a diagnostic
730 marker for non-alcoholic steatohepatitis. *J Gastroenterol Hepatol* 2019;34:1829–35.
- 731 62. Lankinen MA, Stančáková A, Uusitupa M, Ågren J, Pihlajamäki J, Kuusisto J, Schwab
732 U, Laakso M. Plasma fatty acids as predictors of glycaemia and type 2 diabetes.
733 *Diabetologia* 2015;58:2533–44.
- 734 63. Yuan C, Spiegelman D, Rimm EB, Rosner BA, Stampfer MJ, Barnett JB, Chavarro JE,
735 Subar AF, Sampson LK, Willett WC. Validity of a Dietary Questionnaire Assessed by
736 Comparison With Multiple Weighed Dietary Records or 24-Hour Recalls. *Am J*
737 *Epidemiol* 2017;185:570–84.
- 738 64. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent
739 and shared effects of EPA, DPA and DHA. *Front Aging Neurosci* [Internet] 2015 [cited
740 2021 Mar 10];7. Available from:
741 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404917/>
- 742 65. Berg JM, Tymoczko JL, Stryer L. The Citric Acid Cycle. *Biochem 5th Ed* [Internet] W
743 H Freeman; 2002 [cited 2021 Apr 1]; Available from:
744 <https://www.ncbi.nlm.nih.gov/books/NBK21163/>
- 745 66. An Y, Xu W, Li H, Lei H, Zhang L, Hao F, Duan Y, Yan X, Zhao Y, Wu J, et al. High-
746 Fat Diet Induces Dynamic Metabolic Alterations in Multiple Biological Matrices of
747 Rats. *J Proteome Res American Chemical Society*; 2013;12:3755–68.
- 748 67. Guasch-Ferré M, Santos JL, Martínez-González MA, Clish CB, Razquin C, Wang D,
749 Liang L, Li J, Dennis C, Corella D, et al. Glycolysis/gluconeogenesis- and tricarboxylic

- 750 acid cycle–related metabolites, Mediterranean diet, and type 2 diabetes. *Am J Clin Nutr*
751 2020;111:835–44.
- 752 68. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its
753 role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet*
754 *Lond Engl* 1963;1:785–9.
- 755 69. Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ,
756 Moran JH, Mock DM. Plasma concentration of 3-hydroxyisovaleryl carnitine is an early
757 and sensitive indicator of marginal biotin deficiency in humans¹²³⁴. *Am J Clin Nutr*
758 2010;92:1399–405.
- 759 70. Horvath TD, Stratton SL, Bogusiewicz A, Pack L, Moran J, Mock DM. Quantitative
760 Measurement of Plasma 3-Hydroxyisovaleryl Carnitine by LC-MS/MS as a Novel
761 Biomarker of Biotin Status in Humans. *Anal Chem American Chemical Society*;
762 2010;82:4140–4.
- 763 71. Almagro-Moreno S, Boyd EF. Bacterial catabolism of nonulosonic (sialic) acid and
764 fitness in the gut. *Gut Microbes* 2010;1:45–50.
- 765 72. Ottosson F, Brunkwall L, Smith E, Orho-Melander M, Nilsson PM, Fernandez C,
766 Melander O. The gut microbiota-related metabolite phenylacetylglutamine associates
767 with increased risk of incident coronary artery disease. *J Hypertens* 2020;38:2427–34.
- 768 73. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X,
769 Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. *Proc*
770 *Natl Acad Sci National Academy of Sciences*; 2008;105:2117–22.

- 771 74. He M. Pipecolic acid in microbes: biosynthetic routes and enzymes. *J Ind Microbiol*
772 *Biotechnol* 2006;33:401–7.
- 773 75. Ortiz-Castro R, Díaz-Pérez C, Martínez-Trujillo M, Río RE del, Campos-García J,
774 López-Bucio J. Transkingdom signaling based on bacterial cyclodipeptides with auxin
775 activity in plants. *Proc Natl Acad Sci National Academy of Sciences*; 2011;108:7253–8.
- 776 76. Holden MT, Ram Chhabra S, de Nys R, Stead P, Bainton NJ, Hill PJ, Manefield M,
777 Kumar N, Labatte M, England D, et al. Quorum-sensing cross talk: isolation and
778 chemical characterization of cyclic dipeptides from *Pseudomonas aeruginosa* and other
779 gram-negative bacteria. *Mol Microbiol* 1999;33:1254–66.
- 780 77. Edlund A, Garg N, Mohimani H, Gurevich A, He X, Shi W, Dorrestein PC, McLean JS.
781 Metabolic Fingerprints from the Human Oral Microbiome Reveal a Vast Knowledge
782 Gap of Secreted Small Peptidic Molecules. *mSystems* [Internet] American Society for
783 Microbiology Journals; 2017 [cited 2021 Apr 6];2. Available from:
784 <https://msystems.asm.org/content/2/4/e00058-17>
- 785 78. Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive
786 metabolites: opportunities for new therapeutic interventions. *Genome Med* [Internet]
787 2016 [cited 2021 Apr 7];8. Available from:
788 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840492/>

789

790

791

792

793 **Table 1:** Baseline-adjusted least square means of selected metabolites following almond and cracker consumption over 8 weeks

Metabolites ^a	Almond ^b			Cracker			Snack effect P-value (baseline-adjusted) ^c	Time effect P-value (baseline-adjusted)	Snack x Time effect P-value (baseline-adjusted)
	Baseline	Week 4	Week 8	Baseline	Week 4	Week 8			
(2R)-3-Hydroxyisovaleroylcarnitine (x10 ²)	41 ± 17	30 ± 19	27 ± 11	36 ± 15	32 ± 12	32 ± 10	0.001	0.084	0.001
Alpha-tocopherol (x10 ³)	31 ± 12	42 ± 12	39 ± 11	33 ± 11	36 ± 7.9	35 ± 11	0.005	0.147	0.005
CE (16:0) (x10 ²)	46 ± 27	44 ± 24	46 ± 27	37 ± 24	54 ± 27	65 ± 37	0.015	0.241	0.015
Erucic acid (x10 ²)	16 ± 51	20 ± 14	25 ± 23	17 ± 7	17 ± 7	17 ± 6	0.004	0.178	0.004
Indole-3-carboxaldehyde (x10 ²)	5 ± 11	22 ± 58	9 ± 11	3 ± 3	7 ± 7.5	5 ± 3.1	0.002	0.162	0.002
Isomaltose (x10 ¹)	8 ± 32	9 ± 29	11 ± 42	9 ± 5	9 ± 6*	16 ± 22	0.605	<0.001	0.001
LPC (18:0) (x10 ⁴)	58 ± 14	58 ± 19	55 ± 19	54 ± 17	56 ± 18	45 ± 11	0.038	0.002	0.13
Methyl O-D-	27 ± 9	28 ± 10*	21 ± 8	25 ± 10	24 ± 9	24 ± 6	0.911	0.009	0.002

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.03.21256553>; this version posted May 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

galactopyranoside (x10 ²)									
N2,N2-Dimethylguanosine (x10 ¹)	93 ± 54	81 ± 28*	65 ± 18	81 ± 26	70 ± 17	71 ± 17	0.991	0.016	0.001
Oleamide (x10 ³)	9.8 ± 6	27 ± 41	25 ± 29	9.2 ± 52	17 ± 17	14 ± 12	0.014	0.492	0.63
Oxoproline (x10 ⁴)	56 ± 10	62 ± 14*	51 ± 8.6	56 ± 11	59 ± 11	54 ± 10	0.63	<0.001	0.04

794 ^a Metabolites were selected based on overall time effect, FDR<0.05

795 ^b Untransformed means ± standard deviation

796 ^c Linear mixed model analysis with baseline adjustment on transformed data

797 *, P-value <0.05 for week 4 vs. week 8 within same snack group

798

799

800

801

802

803

804

805 **Table 2:** Specific targeted metabolites and their ratios following almond and cracker consumption for 8 weeks

Metabolites	Almond ^a			Cracker			Snack effect P-value (baseline-adjusted) ^b	Time effect P-value (baseline-adjusted)	Snack x Time effect P-value (baseline-adjusted)
	Baseline	Week 4	Week 8	Baseline	Week 4	Week 8	Almond vs. cracker	Week 4 vs. week 8	
Oxylipins									
9-HOTE	0.61 ± 0.37	0.36 ± 0.11	0.39 ± 0.15	0.46 ± 0.14	0.44 ± 0.14	0.41 ± 0.13	0.009	0.814	0.139
15(16)-EpODE	3.4 ± 2.4	2.5 ± 2.1	2.1 ± 1.4	3.4 ± 2.6	3.2 ± 3.0	3.2 ± 3.0	0.016	0.48	0.392
9_10-e-DiHO	6.2 ± 2.3	5.6 ± 2.2	6.2 ± 3.6	7.5 ± 8.2	6.7 ± 4.3	6.9 ± 3.9	0.301	0.444	0.829
9_10-EpO	5.6 ± 3.2	6.0 ± 3.5	9.1 ± 8.9	12.7 ± 20.2	8.5 ± 8.8	6.2 ± 3.6	0.706	0.419	0.048
Non-esterified fatty acids									
ALA	20 ± 11	15 ± 9	13 ± 7	19 ± 8	18 ± 8	15 ± 7	0.014	0.168	0.554
EPA	39 ± 16	28 ± 17	31 ± 15	41 ± 21	36 ± 26	41 ± 21	0.018	0.015	0.718
DHA (x10 ¹)	26 ± 12	19 ± 9	21 ± 8	28 ± 13	25 ± 18	26 ± 13	0.051	0.064	0.914
Endocannabinoids									
DHEA	1.4 ± 0.5	1.1 ± 0.4	1.2 ± 0.4	1.5 ± 0.6	1.4 ± 0.7	1.4 ± 0.5	0.035	0.159	0.986
ALEA	0.23 ± 0.11	0.17 ± 0.08	0.14 ± 0.06	0.21 ± 0.09	0.18 ± 0.08	0.18 ± 0.08	0.126	0.4	0.409
OEA	3.6 ± 1.3	2.8 ± 1.0	3.0 ± 0.9	4.0 ± 1.9	3.0 ± 1.6	3.0 ± 0.8	0.913	0.257	0.799

1/2-OG (x10 ¹)	31 ± 18	23 ± 11	45 ± 22	49 ± 74	27 ± 16	48 ± 31	0.79	<0.001	0.574
Total Fatty Acids (TFA)									
ALA	78 ± 59	63 ± 45	64 ± 35	66 ± 32	76 ± 41	86 ± 78	0.004	0.361	0.58
EPA	28 ± 18	23 ± 19	24 ± 12	29 ± 22	29 ± 15	33 ± 22	0.007	0.169	0.79
DHA (x10 ¹)	11 ± 4	10 ± 5	10 ± 4	12 ± 6	11 ± 5	11 ± 5	0.313	0.441	0.314
ETA (n3)	3.4 ± 3.7	2.5 ± 2.2	3.4 ± 4.5	3.2 ± 2.9	4.1 ± 3.8	7.8 ± 11.3	0.012	0.223	0.561
Palmitoleic acid (x10 ¹)	13 ± 7	10 ± 5	10 ± 7	13 ± 9	14 ± 7	13 ± 10	0.022	0.083	0.15
Oleic acid (x10 ²)	17 ± 6	17 ± 6	18 ± 7	17 ± 8	18 ± 5	17 ± 7	0.632	0.85	0.147
TFA aggregates and activity indices									
Σ (n-6): Σ(n-3)	15 ± 3	16 ± 4	16 ± 3	15 ± 4	14 ± 3	14 ± 4	0.001	0.164	0.724
Σ (n-3) PUFA (x10 ¹)	27 ± 10	23 ± 11	24 ± 9	27 ± 10	27 ± 9	29 ± 16	0.013	0.23	0.593
Palmitoleic acid/Palmitic acid (C16:1n7/C16:0)	0.072 ± 0.025	0.06 ± 0.021	0.057 ± 0.021	0.067 ± 0.023	0.073 ± 0.063	0.06 ± 0.02	0.004	0.014	0.219
Elaidic acid/ Stearic acid (C18:1n9/C18:0)	3.1 ± 0.9	3.3 ± 1.3	3.1 ± 0.7	3.0 ± 0.7	3.3 ± 0.9	3.3 ± 0.8	0.446	0.544	0.643
γ-Linolenic	0.009 ± 0.006	0.009 ± 0.007	0.01 ± 0.006	0.011 ± 0.006	0.011 ± 0.007	0.011 ± 0.006	0.379	0.066	0.304

acid/linoleic acid (C18:3n6/C18:2n6)									
Adrenic	0.028 ± 0.008	0.029 ± 0.01	0.028 ± 0.009	0.029 ± 0.01	0.03 ± 0.01	0.028 ± 0.01	0.99	0.242	0.567
acid/arachidonic acid (C22:4n6/C20:4n6)									
DHA/DPA	2.4 ± 0.8	2.7 ± 1.0	2.6 ± 0.9	2.7 ± 0.969	2.6 ± 0.9	2.8 ± 1.3	0.068	0.523	0.583
(C22:6n3/C22:5n3)									
DPA/EPA	2.0 ± 0.7	2.1 ± 0.7	2.0 ± 0.8	2.0 ± 0.8	1.9 ± 0.9	1.8 ± 1.2	0.026	0.267	0.388
(C22:5n3/C20:5n3)									

806 ^a Untransformed means ± standard deviation

807 ^b Linear mixed model analysis with baseline-adjustment on transformed data

808 n3, omega 3

809

810

811

812 **Table 3:** Chemical similarity enrichment analysis results of significant clusters of untargeted serum metabolites measured following almond and
 813 cracker consumption over 8 weeks

Cluster name	Cluster size	P-value (KS)	FDR adjusted P-value (KS)	No. of altered metabolites in cluster	Metabolites	P-value (almond vs. cracker) ^a
Unsaturated phosphatidylcholines	90	<0.001	<0.001	Increased: 17	PC (p-40:5)	0.004
					PC(40:7)	0.007
					PC(p-38:4)/PC(o-38:5) A	0.009
					PC(38:7)	0.011
					PC(p-36:1)/PC(o-36:2)	0.012
					PC(p-38:4)/PC(o-38:5) B	0.015
					PC(p-40:4)/PC(o-40:5)	0.024
					PC(p-36:4)/PC(o-36:5)	0.026
					PC(p-36:2)/PC(o-36:3)	0.029
					PC(p-38:5)/PC(o-38:6)	0.031
					PC(p-44:4)/PC(o-44:5)	0.033
					PC(39:4)	0.036
					PC (p-36:3) or PC (o-36:4)	0.036
					PC (p-34:2) or PC (o-34:3)	0.041
					PC(p-40:6)/PC(o-40:7)	0.041
					PC(p-34:2)/PC(o-34:3)	0.048
					PC (p-42:3) or PC (o-42:4)	0.049
Unsaturated triglycerides	84	<0.001	<0.001	Increased: 13	TG(56:4)	0.002
					TG(58:8)	0.005
					TG(18:1/18:2/20:3)	0.009
					TG(54:3)	0.009
					TG(54:4)	0.013
					TG(58:9)	0.014
					TG(56:5)	0.025
					TG(56:3)	0.028
					TG (53:5)	0.03
					TG(56:7)	0.033
					TG(18:2/20:3/22:6)	0.044

					TG(18:1/18:2/19:1)	0.046
					TG(56:6)	0.049
Sphingomyelins	24	<0.001	<0.001	Increased: 5	SM(d38:1)	0.021
					SM(d40:1)	0.024
					SM (d37:1)	0.027
					SM(d42:1)	0.033
					SM(d40:2)	0.041
Unsaturated lysophosphatidylcholines	14	<0.001	0.004	Increased: 3	LPC (16:1)	0.029
					LPC (17:1)	0.032
					LPC (20:1)	0.041
Saturated lysophosphatidylcholines	6	<0.001	<0.001	Increased: 2	LPC (18:0)	0.038
					LPC (16:0)	0.011
Tricarboxylic acids	3	<0.001	0.001	Increased: 3	Citric acid	0.004
					Aconitic acid	0.046
					Isocitric acid	0.015
Tocopherols	3	0.006	0.046	Increased: 1 Decreased: 1	Gamma-tocopherol	0.005
					Alpha-tocopherol	0.005

814 a, baseline-adjusted overall snack effect

815 KS, Kolmogorov–Smirnov test; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; SM, sphingomyelin; TG, triglycerides

816

817

818

819 Figure legends

820 Figure 1: Biochemical network displaying differences between almond and cracker groups over 4 and 8 weeks. Metabolites are connected based on
821 biochemical relationships (orange, KEGG RPAIRS), measured structural similarity (blue, Tanimoto coefficient ≥ 0.7), or manually annotated structural
822 similarity (grey). Metabolite size denotes the effect size (Hedge's g , almond vs cracker group). Metabolite color represents the direction of the effect size i.e.
823 blue, almond > cracker overall ($P < 0.05$); red, almond < cracker overall ($P < 0.05$). Numbers denote the time point at which the significant i.e. ($P < 0.05$) time x
824 snack effect was observed i.e., 4, week 4; 8, week 8; no number represents significant overall snack effect. P-values are derived from the baseline-adjusted
825 linear mixed model analysis. Shapes display primary metabolic pathways or structural superclass designations obtained via ClassyFire. Metabolites
826 potentially produced by the gut microbiome are highlighted with thick black borders. Clusters of metabolites are circled. Significant metabolites which did
827 not have KEGG identifiers are included as independent nodes with manually annotated edges in their respective pathway clusters.

